Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 6/20 | 0.62 |
| ▸ | TBXA2R | P21731 | 4/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | CCR9 | P51686 | 1/20 | 0.43 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4929621 | 0.90 | DRD2 (0.52) | DRD2TBXA2RLMNASMN1; SMN2TP53 | |
| SCHEMBL4925606 | 0.89 | DRD2 (0.52) | DRD2TBXA2RLMNASMN1; SMN2TP53 | |
| SCHEMBL4933054 | 0.86 | LMNA (0.49) | DRD2TBXA2RLMNASMN1; SMN2TP53 | |
| SCHEMBL4931374 | 0.85 | LMNA (0.48) | DRD2TBXA2RLMNASMN1; SMN2TP53 | |
| SCHEMBL4927356 | 0.82 | DRD2 (0.45) | DRD2TBXA2R | |
| SCHEMBL4924964 | 0.82 | KMT2A (0.52) | SMN1; SMN2 | |
| SCHEMBL4933411 | 0.82 | MAPT (0.55) | DRD2TBXA2RTP53MAPTTHRB | |
| SCHEMBL4929300 | 0.82 | MAPT (0.47) | DRD2TBXA2RLMNASMN1; SMN2TP53 | |
| SCHEMBL4929907 | 0.81 | DRD2 (0.62) | DRD2TBXA2RLMNASMN1; SMN2TP53 | |
| SCHEMBL4931851 | 0.81 | KMT2A (0.50) | SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080021069-A1 | Receptor Function Regulating Agent | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-01-24 | — | — | US | disclosed |
| US-20080021069-A1 | Receptor Function Regulating Agent | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-01-24 | — | — | US | disclosed |
| US-20080021069-A1 | Receptor Function Regulating Agent | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-01-24 | — | — | US | disclosed |
| EP-1810677-A1 | RECEPTOR FUNCTION REGULATING AGENT | Takeda Pharmaceutical Company Limited (JP) | 2007-07-25 | — | — | EP | disclosed |
| EP-1810677-A1 | RECEPTOR FUNCTION REGULATING AGENT | Takeda Pharmaceutical Company Limited (JP) | 2007-07-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080021069-A1 | Receptor Function Regulating Agent | GPR119, INSR, GPR65 | DRD2 2198/4885TBXA2R 354/4885LMNA 4744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.